(firstQuint)PT001 MDI Versus Spiriva in Patients With Moderate to Severe COPD.

 The primary objective of this study is to assess efficacy relative to placebo of GP MDI in subjects with moderate to severe chronic obstructive pulmonary disease (COPD) within the range of doses evaluated in this protocol.

 To this end, each dose of GP MDI will be compared to placebo with respect to the primary efficacy endpoint, FEV1 AUC0-12 relative to baseline.

.

 PT001 MDI Versus Spiriva in Patients With Moderate to Severe COPD@highlight

The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.

